Navigation Links
Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

Leading Expert Discusses Study During Late-Breaking Presentations at ACC

CHICAGO, April 1, 2008 /PRNewswire/ -- Final six-month, follow-up patient data presented today during the late-breaking clinical trial sessions at the American College of Cardiology, suggest MyoCell(R) myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.

The findings from the SEISMIC(1) Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe, evaluated MyoCell myoblast clinical cell therapy delivered via the MyoCath(R), endoventricular needle-injection catheter in patients previously fitted with implanted cardiac defibrillators(ICDs), receiving standard medical therapy and who are experiencing congestive heart failure. On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in the control group. All patients were experiencing congestive heart failure and were previously fitted with ICDs and receiving standard medical therapy. Both the MyoCell biologic therapy and the MyoCath needle-injection catheter, developed by Bioheart, Inc., are currently being studied as investigational products.

"The results from the SEISMIC Trial are encouraging," said Prof. Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. "While the study was specifically designed to show safety, the findings also suggest positive trends in clinical benefits when evaluating the treated group versus the control group at six months."

Patients in both groups were evaluated at three- and six-month intervals using a variety of tests, i
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
3. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
4. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
5. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
6. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... WOONSOCKET, R.I. , Oct. 2, 2014  MinuteClinic, the largest ... the United States , has opened its first walk-in clinics ... two CVS/pharmacy stores in Corpus Christi and ... Corpus Christi in December. The ... new clinics nationwide in 2014. With the Corpus Christi ...
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
(Date:10/2/2014)... Oct. 1, 2014 The global high content ... by the ,Threat of Obsolescence, wherein technologies as well ... Pharmaceutical and biotechnology companies as well as academic and ... screening as a powerful research tool in drug discovery. ... segment in the high content screening market. In high ...
Breaking Medicine Technology:First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 2First MinuteClinic Walk-in Medical Clinics Open in Corpus Christi 3Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 2High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services - Global Forecasts to 3
... TUMWATER, Wash., Dec. 13, 2011  The Washington Health Care ... COMS Interactive , LLC (COMS or Clinical ... is in alignment with WHCA,s stated objective, which is ... provide long-term health care residents with the highest quality ...
... 2011 IsZo Capital Management LP, one of the largest ... TAROF ), announced today that it delivered the following ... it withdraw immediately from the agenda for the upcoming annual ... December 13, 2011 Board of Directors of Taro ...
Cached Medicine Technology:WHCA Selects COMS Interactive as Affinity Partner 2WHCA Selects COMS Interactive as Affinity Partner 3IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 2IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 3IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 4IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders' Meeting 5
(Date:10/2/2014)... 2014 Robins & Morton received ... Builders and Contractors (ABC) of Alabama. , ABC ... held at Sheraton Birmingham Hotel., , ... Million to $25 Million, Obelisk Award (First Place) ... Government $10 Million to $25 Million, Obelisk Award ...
(Date:10/2/2014)... Amy Norton HealthDay Reporter ... girls free birth control -- especially long-acting implanted devices -- ... current U.S. average, new findings suggest. In a study ... contraceptives substantially cut the girls, rates of unplanned pregnancy and ... per 1,000 girls -- versus a rate of 158 per ...
(Date:10/2/2014)... 1, 2014 (HealthDay News) -- Children with autism are ... fully capable of being more active, a small study ... of 29 children, some with autism and some without. ... of moderate physical activity and 70 more minutes each ... children with autism scored lower on strength, but had ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... Hospitals that pull out all the stops to rescue ... lives, but the cost of such heroism is questionable, ... about 5 percent better at saving elderly patients with ... operate with less intensity, said senior author Dr. Amir ...
(Date:10/1/2014)... associated with Alzheimer,s disease; however, researchers are still looking ... agent of the onset and development of the disease. ... is not harmful when found in isolation but only ... form the so-called amyloid fibrils , "We are not ... multiple ones because each aggregate of peptide, which can ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 2Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 3Health News:Free, Long-Acting Contraceptives May Greatly Reduce Teen Pregnancy Rate 4Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 2Health News:'High-Intensity' Hospitals Save More Elderly After Surgery: Study 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2
... Persons treated with Interferon (IFN)to treat chronic hepatitis C ... phase itself//. Retinopathy can develop within two weeks from commencement ... in the journal Investigative Ophthalmology & Visual Science (IOVS)in the ... in Japan gauged the changes in diameter of ...
... more daughters and no sons, may have a greater risk ... team of Israeli researchers compared families of men diagnosed with ... daughters and risk of prostate cancer were related. ... may be a link but the factors responsible for prostate ...
... a little gadget that can be used for 15 minutes ... device, developed by New York based company Helicor, is under ... users to lower their own heartbeat by regulated deep breathing, ... device, also on trial for several other conditions including anxiety ...
... in maintaining weight and a healthy lifestyle. On the same ... and diuretics are superfluous with no proven benefits. , ... alcohol as a temporary measure to freshen up the kidneys ... to pump the body with more antioxidants. Drinking lots of ...
... a premature baby is up for women who have ... eliminate precancerous cells, called LEEP or loop// incision, researchers ... a study involving 5000 women, researchers said that nearly ... incision was avoided. Babies born prematurely are seen battling ...
... girls might want to have another look at that ... to recent studies, teenage girls who read articles on ... prone to resort to drastic weight reducing techniques such ... who don’t. ,The study, published in Pediatrics' January ...
Cached Medicine News:Health News:Gender Of Children May Be Linked To Risk Of Prostate Cancer 2Health News:Drop That Glossy, Girl! 2
Straight shafts with 1 x 2 teeth. Serrated handle, non-magnetic and polished finish....
Straight shafts with pointed 4.5 mm tying surfaces. Scalloped wide handle with dull finish....
Straight shafts with 0.5 mm teeth and 6 mm tying platform. Wide serrated handle with thumb catch lock and polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: